Jardiance ® (empagliflozin) approved in Europe for the treatment of heart failure with reduced ejection fraction
The European Commission has granted marketing authorization for Jardiance® (empagliflozin) as a treatment for adults with symptomatic chronic heart failure with reduced ejection fraction (systolic heart failure), Boehringer Ingelheim and Eli Lilly and Company have announced.The extension of the indication follows a positive recommendation by the Committee for Medicinal Products for Human Use (CHMP) on 20 May 2021.2
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210621005298/en/
“Today’s approval provides an important new treatment option which can now help the millions of people in Europe living with symptomatic chronic heart failure with reduced ejection fraction,” said Faiez Zannad, M.D., Ph.D., EMPEROR Program clinical investigator and Emeritus Professor of Therapeutics at the University of Lorraine, France. “New treatment options such as empagliflozin can save lives and help people spend less time in the hospital and more time with their families.”
Marketing authorization is based on results from the EMPEROR-Reduced trial in which empagliflozin showed a significant 25 percent reduction in the combined relative risk versus placebo of cardiovascular death or hospitalization due to heart failure.3 The findings from the primary endpoint were consistent in subgroups with or without type 2 diabetes. Key secondary endpoint analyses from the trial demonstrated that empagliflozin reduced the relative risk of first and recurrent hospitalization for heart failure by 30 percent and significantly slowed kidney function decline.3
“Jardiance was the first SGLT2 inhibitor to demonstrate cardiovascular protective effects and improve cardiovascular outcomes in patients with type 2 diabetes,” said Waheed Jamal, M.D., Corporate Vice President and Head of CardioMetabolic Medicine, Boehringer Ingelheim. “We are delighted to now be able to offer Jardiance to people with heart failure with reduced ejection fraction, regardless of diabetes status. We look forward to collaborating with regulators in Europe and beyond to ensure access to this trusted therapy.”
“As we enter this new chapter of heart failure management, we can now look ahead to results from the EMPEROR-Preserved trial, expected this year. This trial will explore empagliflozin in heart failure with preserved ejection fraction, in adults with or without diabetes,” continued Jeff Emmick, M.D., Ph.D., Vice President, Product Development, Lilly. “We are committed to finding solutions for the millions of people who live with heart failure and important metabolic conditions around the world.”
Heart failure is often associated with other diseases of the cardio-renal-metabolic systems such as type 2 diabetes and kidney disease. Due to the interconnected nature of these systems, improvement in one system can lead to positive effects throughout the others. Heart failure is a very common and severe complication of a heart attack4,5 and occurs when the heart cannot pump sufficient blood to the rest of the body. There are two forms of the condition; heart failure with reduced ejection fraction means the heart cannot contract normally, while preserved ejection fraction means the heart cannot properly fill with blood. People with heart failure often experience breathlessness and fatigue, which can severely impact their quality of life.6,7
The EMPEROR-Reduced trial is part of the EMPOWER clinical program, the broadest and most comprehensive of any SGLT2 inhibitor, exploring the impact of empagliflozin on the lives of people across the spectrum of cardio-renal-metabolic conditions.
About the EMPEROR Heart Failure Studies8,9
The EMPEROR (EMPagliflozin outcomE tRial in patients with chrOnic heaRt failure) heart failure studies are two Phase III, randomized, double-blind trials investigating once-daily empagliflozin compared with placebo in adults with heart failure with preserved or reduced ejection fraction, with or without diabetes, who are receiving current standard of care:
- EMPEROR-Reduced [NCT03057977] investigated the safety and efficacy of empagliflozin in patients with chronic heart failure with reduced ejection fraction (HFrEF).
- Primary endpoint: time to first event of adjudicated cardiovascular death or adjudicated hospitalization for heart failure
- Number of patients: 3,730
- Completion: 2020
- Link to lay summary
- EMPEROR-Preserved[NCT03057951] investigated the safety and efficacy of empagliflozin in patients with chronic heart failure with preserved ejection fraction (HFpEF).
- Primary endpoint: time to first event of adjudicated cardiovascular death or adjudicated hospitalization for heart failure
- Number of patients: 5,988
- Completion: 2021
About the EMPOWER Program
The Alliance has developed the EMPOWER program to explore the impact of empagliflozin on major clinical cardiovascular and renal outcomes in a spectrum of cardio-renal-metabolic conditions. Cardio-renal-metabolic conditions are the leading cause of mortality worldwide and account for up to 20 million deaths annually.10 Through the EMPOWER program, Boehringer Ingelheim and Lilly are working to advance knowledge of these interconnected systems and create care which offers integrated, multi-organ benefits. Comprised of eight clinical trials and two real-world evidence studies, EMPOWER reinforces the long-term commitment of the Alliance to improve outcomes for people living with cardio-renal-metabolic conditions. With more than 400,000 adults studied worldwide in clinical studies, it is the broadest and most comprehensive clinical program for an SGLT2 inhibitor to date.
About Heart Failure
Heart failure is a progressive, debilitating and potentially fatal condition that occurs when the heart cannot supply adequate circulation to meet the body’s demands for oxygenated blood, or to do so requires increased blood volume leading to fluid accumulation (congestion) in the lungs and peripheral tissues.4 It is a widespread condition affecting over 60 million people worldwide and expected to increase as the population ages. Heart failure is highly prevalent in people with diabetes;11 however, approximately half of all people with heart failure do not have diabetes.12
About Cardio-Renal-Metabolic Conditions
Boehringer Ingelheim and Lilly are driven to transform care for people with cardio-renal-metabolic conditions, a group of interconnected disorders that affect more than one billion people worldwide and are a leading cause of death.10
The cardiovascular, renal and metabolic systems are interconnected, and share many of the same risk factors and pathological pathways along the disease continuum. Dysfunction in one system may accelerate the onset of others, resulting in progression of interconnected diseases such as type 2 diabetes, cardiovascular disease, heart failure, and kidney disease, which in turn leads to an increased risk of cardiovascular death. Conversely, improving the health of one system can lead to positive effects throughout the others.13,14
Through our research and treatments, our goal is to support people’s health, restoring the balance between the interconnected cardio-renal-metabolic systems and reducing their risk of serious complications. As part of our commitment to those whose health is jeopardized by cardio-renal-metabolic conditions, we will continue embracing a multidisciplinary approach towards care and focusing our resources on filling treatment gaps.
Empagliflozin (marketed as Jardiance®) is an oral, once-daily, highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor and the first type 2 diabetes medicine to include cardiovascular death risk reduction data in its label in several countries.15,16,17
Please click on the following link for ‘Notes to Editors’ and ‘References’ https://www.boehringer-ingelheim.com/press-release/reduced-heart-failure-treatment-approval-europe
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Product Communication Manager
Phone: +49 (6132) 77 172209
Senior Director of Communications
Eli Lilly and Company
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bob Slinn Joins FunPlus Senior Leadership Team as Vice President of Business Development4.8.2021 17:15:00 CEST | Press release
FunPlus, a leading independent mobile game developer and publisher, today announced that Bob Slinn has been appointed as Vice President of Business Development for the company. As a member of the company’s senior leadership team headquartered in Switzerland, Slinn will report to Chief Business Officer Chris Petrovic and be responsible for leading the company’s Western market strategic business development efforts. These efforts will include managing and expanding FunPlus’ growing list of global IP partners and deepening the company’s platform relationships, as well as leading developer relations efforts in support of the company’s ongoing strategic investment and M&A activities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210804005425/en/ Bob Slinn Joins FunPlus Senior Leadership Team as Vice President of Business Development (Photo: Business Wire) “We’re delighted to welcome Bob to the team in a leadership role that is t
Tigo Energy Unveils Energy Intelligence Platform to Simplify Fleet Management4.8.2021 16:00:00 CEST | Press release
Tigo Energy, Inc., the solar industry’s worldwide leader in Flex MLPE (Module Level Power Electronics), today unveiled its Energy Intelligence (EI) Solution, a comprehensive digital platform designed to optimize the installer experience around commissioning, monitoring, and maintaining fleets of solar installations. For solar installers, operations and maintenance represents a significant and ongoing burden due to the lack of visibility to the module-level information. Tigo EI quickly identifies issues that increase truck rolls, undermine energy output, and undercut the economic success of said installations. EI also delivers the tools to decrease operation and maintenance costs, increase system performance and revenue, and improve the user experience for both installers and customers. The platform also simplifies the commissioning process by providing greater system visibility and information to end installers and EPCs. “Fleet management technology is the next key enabler in renewable
Avex Releases 100% Hemp Cloth T-shirt4.8.2021 16:00:00 CEST | Press release
Avex Entertainment Inc. began limited sales from July 30 of the T-shirts from a Japanese fabric brand "majotae" (pronounced "ma-yo-tah-e") on its official website, using hemp*1, the natural, sustainable material that is gaining attention globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210804005064/en/ 100% hemp cloth T-shirt made by majotae (Photo: Business Wire) By maximizing the company's knowhow in creating entertainment contents, Avex shares with the world a new concept in sustainability—hemp cloth, which combines both comfort as clothing, and earth-friendly, ecological aspects. Avex is cultivating a brand new field of business that creates moving experiences beyond the field of entertainment. About majotae Majotae is a brand that utilizes modern technology to resurrect the true texture of the hemp cloth that Japanese people have used since ancient times. The greatest feature of "majotae" is its realization of a
Q4 Launches Suite of ESG Communications Products4.8.2021 15:00:00 CEST | Press release
Q4 Inc. (Q4), a leading capital markets communications platform, announced the first phase of new products that standardize how public companies can deliver information regarding their environmental, social and governance (ESG) efforts. At a time of extensive data collection, heightened investor emphasis and mounting regulatory mandates around ESG disclosure, public companies are challenged with what and how best to communicate their social impact and sustainability programs. Similarly investors are taxed with distilling the vast amount of ESG-related information relevant to their investment criteria. In its fundamental commitment to ESG, both as an organization and on behalf of its clients, Q4 has introduced the first of several new offerings that enable public companies to effectively tell their ESG story in a format that makes it easier for investors to consume. Working in tandem with its leading clients, Q4 has established a set of best practice, industry-focused templates for corp
Enedym, Inc. Announces Two New Appointments To Board of Directors4.8.2021 14:00:00 CEST | Press release
Enedym, Inc. (“Enedym”), the technology company thatdevelops next generation switched reluctance motors (SRMs), electric propulsion, and electrified powertrains, announced today that it has appointed Robert Lee, former Vice President of Engines, Electrified Propulsion, and Advanced Powertrain Engineering at Fiat Chrysler Automobiles (FCA) and Ron Harper, President and CEO of JFE Shoji Power Canada Inc., to its board of directors. "We are so pleased to welcome Bob and Ron as new directors to Enedym’s board," said Ali Emadi, Founder, President, and CEO of Enedym. "They join Enedym at an exciting time as we expand our operations and development capabilities in order to continue to transform the electric motor and electrified powertrain sector. Bob’s deep experience in the global automotive sector will bring valuable experience to our rapidly growing automotive electrification business. Ron’s expertise in manufacturing and supply chain management will be valuable in developing Enedym’s eme
yellow.ai Raises $78.15M to Deliver Total Customer Experience Automation4.8.2021 13:33:00 CEST | Press release
yellow.ai, the world’s leading customer experience (CX) automation platform, trusted by 700+ enterprises globally, today announced it has raised $78.15M in Series C, led by WestBridge Capital along with Sapphire Ventures, and Salesforce Ventures. Lightspeed Venture Partners again participated in this round, which brings total funding raised so far to $102.15M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210804005587/en/ Raises $78.15M to Deliver Total CX Automation (Graphic: Business Wire) yellow.ai enables enterprises to leverage its proprietary NLP engine and platform to build chatbots and voice bots, in 100+ languages, across 35+ channels that automate functions like Customer Support, Customer Engagement, Conversational Commerce, and Employee Experience. The platform comes pre-integrated with enterprise applications like Salesforce, Shopify, Cisco, Avaya, SharePoint, and 100 more. Since its prior funding round, yellow.
ANYbotics Boosts Autonomous Mobile Robots with Velodyne Lidar Sensors4.8.2021 12:48:00 CEST | Press release
Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today announced ANYbotics is equipping its autonomous mobile robots with Velodyne’s Puck™ lidar sensors. ANYbotics robots provide industrial operators with an automated robotic inspection solution to support efforts in monitoring and maintaining plants. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210804005237/en/ Equipped with Velodyne Lidar’s Puck™ sensors, ANYbotics’ four-legged robot ANYmal performs inspection and monitoring tasks in challenging industrial terrains such as mining and minerals, oil and gas, chemicals, energy and construction. (Photo: ANYbotics) ANYbotics’ four-legged robot ANYmal performs inspection and monitoring tasks in challenging industrial terrains such as mining and minerals, oil and gas, chemicals, energy and construction. ANYmal’s legs provide unparalleled mobility when moving up and down stairs, climbing over obstacles, steps and gaps, and crawling in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom